|
General characteristics
| | | | |
|
Age
|
60.2 ± 14.6, 62 (18–89)
|
59.3 ± 14.6, 62 (18–84)
|
60.4 ± 14.7, 62 (18–89)
|
0.775
|
|
Gender (male)
|
59.3%
|
43.5%
|
62.0%
|
0.018
|
|
Type of malignancy
| | | |
0.609
|
|
Hematological
|
61.8%
|
65.3%
|
61.3%
| |
|
Solid tumor
|
38.2%
|
34.7%
|
38.7%
| |
|
Metastatic disease
|
72.7%
|
56.3%
|
75.2%
|
0.112
|
|
Active disease (no remission)
|
86.8%
|
86.9%
|
86.7%
|
0.965
|
|
Stem cell transplant (yes)
|
31.6%
|
26.1%
|
18.5%
|
0.284
|
|
Co-morbidity index ≥ 5
|
68.5%
|
63.0%
|
69.4%
|
0.393
|
|
Chemotherapy within 10 days
|
24.3%
|
41.3%
|
21.4%
|
0.0036
|
|
CNS malignancy involvement**
|
26.5%
|
39.0%
|
24.4%
|
0.0358
|
|
Medical history of seizure disorder
|
10.4%
|
13.0%
|
9.9%
|
0.527
|
|
Admission diagnosis
| | | | |
|
Altered mental status
|
30.9%
|
60.9%
|
25.8%
|
< 0.0001
|
|
Respiratory failure
|
25.9%
|
4.3%
|
29.5%
| |
|
Severe sepsis/shock
|
18.0%
|
10.9%
|
19.2%
| |
|
Cardiac arrest
|
11.7%
|
10.9%
|
11.8%
| |
|
Stroke (hemorrhagic or ischemic)
|
2.8%
|
6.5%
|
2.2%
| |
|
Other
|
10.7%
|
6.5%
|
11.5%
| |
|
Variables during ICU stay
| | | | |
|
Days from admission to EEG***
|
5.5 ± 7.5, 3 (1–69)
|
3.9 ± 5.3, 2 (1–30)
|
5.7 ± 7.8, 3 (1–69)
|
0.141
|
|
SOFA on admission#
|
8.5 ± 3.7, 8 (0–19)
|
7.7 ± 3.1, 7 (1–15)
|
8.6 ± 3.8, 9 (1–19)
|
0.170
|
|
SOFA at time of EEG#
|
9.9 ± 4.0, 10 (3–22)
|
8.5 ± 3.1, 8 (3–15)
|
10.2 ± 4.1, 10 (3–22)
|
0.0129
|
|
GCS at time of EEG (median)^
|
7 (3–12)
|
7 (3–12)
|
7 (3–12)
|
0.720
|
|
Vasopressors (yes)
|
56.5%
|
36.9%
|
59.8%
|
0.0039
|
|
Acute renal failure (yes)
|
52.4%
|
30.4%
|
56.1%
|
0.0013
|
|
Mechanical ventilation (yes)
|
79.5%
|
69.6%
|
81.2%
|
0.071
|
|
Use of sedatives (yes)
|
49.8%
|
36.9%
|
52.0%
|
0.059
|
|
Cardiac arrest during ICU stay
|
13.2%
|
10.9%
|
13.7%
|
0.814
|
|
Abnormal brain imaging
|
47.0%
|
60.9%
|
44.6%
|
0.0416
|
|
Meningitis/encephalitis
|
4.1%
|
8.7%
|
3.3%
|
0.103
|
|
Medications given in the ICU ^^
|
31.9%
|
39.1%
|
30.6%
|
0.253
|
|
Abnormal electrolytes
|
4.4%
|
4.3%
|
4.4%
|
1
|
|
PRES+
|
1.3%
|
2.2%
|
1.1%
|
0.467
|
|
CNS malignancy involvement
|
26.5%
|
39.0%
|
24.4%
|
0.0358
|
|
CAR T cell therapy++
|
4.7%
|
15.2%
|
2.9%
|
0.0003
|
|
Outcomes
| | | | |
|
Improvement of GCS prior to discharge
|
44.2%
|
52.2%
|
42.8%
|
0.237
|
|
ICU Length of stay
|
13.8 ± 13.8
|
12.5 ± 11.5
|
14.1 ± 14.2
|
0.655
|
|
Hospital Length of stay
|
22.3 ± 21.2
|
21.3 ± 18.4
|
22.5 ± 21.7
|
0.857
|
|
Overall mortality
|
60.9%
|
45.7%
|
63.5%
|
0.022
|
